Latest Observability News

Nimy Resources advances its Mons Project with significant high-grade copper and gallium mineralisation confirmed at Masson and Block 3 East prospects, supported by a successful capital raise and a CSIRO research grant.

Askari Metals reports significant exploration advances across its Australian gold and copper projects and secures a new uranium project in Tanzania, supported by fresh funding and leadership updates.

Torque Metals delivers standout drilling results at its Paris Gold Project, confirming high-grade gold zones beyond existing resources, while bolstering its portfolio with new gold and lithium tenements and a successful $1M share placement.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Apollo Minerals reports exceptional drilling results at its Salanie Gold Project in Gabon, revealing high-grade gold mineralisation and securing $1.25 million through a recent entitlement offer.

Avecho Biotechnology progresses its Phase III clinical trial for a TPM®-enhanced CBD insomnia capsule, expands patient recruitment, and completes a major manufacturing campaign for its U.S. partner Ashland.

RLG Ltd has successfully raised $900,000 through a two-tranche placement to fund the development of its food and health products and expand global sales channels. The second tranche, involving options issuance, awaits shareholder approval.

88 Energy Limited announces a maiden internal Prospective Resource estimate of 283 million barrels of oil for its Canning Prospect at Project Leonis, Alaska, with plans to drill the Tiri-1 exploration well targeting multiple reservoirs in 2026.

Alterity Therapeutics has announced encouraging Phase 2 trial results for ATH434, showing significant slowing of disease progression in multiple system atrophy (MSA) patients and a strong safety profile. These findings mark a potential breakthrough in treating a disease with no approved therapies.

Argenica Therapeutics has received a positive safety review from its independent DSMB for the Phase 2 trial of ARG-007 in acute ischaemic stroke patients, with dosing now 86% complete and full recruitment expected by early Q2 2025.

Southern Cross Gold Consolidated has reported exceptional high-grade gold intersections from deep drilling at its Christina prospect, confirming robust mineralization extending 350 metres below previous hits and expanding the Sunday Creek project's footprint.

Nickel Industries reveals a substantial Exploration Target of 350 to 700 million dry metric tonnes at 0.9% to 1.1% nickel for its Sampala Project, complementing an existing 187 million dmt resource. The company has initiated mine development and haul road construction, positioning itself for a secure nickel supply chain.